An internationally recognised urological cancer expert will deliver a free educational webinar on metastatic hormone-sensitive prostate cancer for healthcare professionals.
Professor Giuseppe Luigi Banna is a leading Consultant Medical Oncologist specialising in Urology and Lung tumours who chairs the International Urology Cancer Summit which provides free education to individuals involved in caring for people with urological cancers.
He has now joined forces with Oncology News Today to deliver a webinar on ‘Selecting doublet vs triplet therapy in metastatic hormone-sensitive prostate cancer (mHSPC)’ which will explore the systemic therapy options.
Professor Banna, who holds positions at the Department of Oncology in Portsmouth Hospitals University NHS Trust and as an Honorary Associate Professor at the Faculty of Science and Health, School of Pharmacy and Biomedical Sciences at the University of Portsmouth, said: “During this webinar we’ll review key clinical trials and highlight outcomes like overall survival and progression-free survival across diverse patient populations.
“The discussion will include considerations for treatment personalisation based on disease volume and genomic biomarkers.
“Emerging imaging modalities and their impact on staging will also be addressed, along with insights into future therapeutic strategies leveraging biomarker-driven approaches.”
The webinar will help attendees to learn about:
- Improved Survival with Systemic Therapy Intensification: Clinical trials have demonstrated significant survival benefits from intensifying systemic therapy in mHSPC. Both doublet and triplet regimens, incorporating androgen deprivation therapy (ADT) with agents like docetaxel, darolutamide, abiraterone, apalutamide or enzalutamide, have shown enhanced overall survival and progression-free survival, especially in high-volume disease settings.
- Role of Advanced Imaging in Staging: Next-generation imaging modalities, such as PSMA PET/CT and whole-body MRI, have led to stage migration by detecting metastases more accurately than conventional imaging methods. This improved staging impacts treatment decisions and may refine the identification of patients suitable for systemic or metastasis-directed therapies.
- Personalised Treatment Strategies: Emerging approaches focus on tailoring therapy based on genomic biomarkers (e.g BRCA mutations, PTEN loss) and patient characteristics like frailty or disease volume. These strategies aim to optimize treatment efficacy while minimising toxicity, particularly in older or vulnerable populations.
Oncology News Today event manager Emily Mayhew said: “Professor Banna has led more than 20 clinical and translational studies for urology and lung cancer as Principal Investigator and his dedication to scientific advancement is reflected in his publication of more than 230 scientific papers in peer-reviewed and indexed journals.
“He has also helped to create the International Urology Cancer Summit which helps hundreds of healthcare professionals every year to learn about the latest advancements and breakthrough treatments from world-leading speakers for free.
“Professor Banna is known for being a compassionate and skilled medical professional who works hard to provide patients with the best individualised treatment and support and this is a fantastic opportunity to benefit from his expertise.”
The free webinar with Professor Banna will take place from 12.30pm to 1.30pm BST on Tuesday, June 17.
Healthcare professionals can book their free place at https://www.tickettailor.com/events/orangejuicecommunications/1683632.
